The Group's sales for the period amounted to SEK 131 (180) million. EBITDA amounted to SEK 18 (28) million. Operating profit totalled SEK 11 (23) million. The net profit after tax for the period amounted to SEK -3 (9) million Earnings per share after tax for the period were SEK -0.01 (0.03 ) before and after dilution Significant events during the period The Board decided to initiate a process to review the communicated financial targets. Significant events after the period The Board has appointed Maris Hartmanis as BioPhausia's new CEO. Niklas Prager has been proposed as the new Chairman of the Board of BioPhausia. BioPhausia has become the main supplier of parallel-imported pharmaceuticals to Apoteksgruppen [HUG#1414656]
Interim report January - March 2010
| Source: BioPhausia AB